Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tofacitinib dose reduction versus continued 10 mg BID in ulcerative colitis remission
2017-002274-39Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Oct 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tofacitinib in autoimmune colitis (3 arms), sponsored by Pfizer. Primary endpoint: Remission based on modified Mayo score at Month 6. Started Oct 2017; status: terminated.
02
Drugs
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2017-002274-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-002274-39.